financetom
Business
financetom
/
Business
/
Keysight agrees to buy Britain's Spirent for $1.5 bln
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Keysight agrees to buy Britain's Spirent for $1.5 bln
Mar 28, 2024 12:39 AM

March 28 (Reuters) - U.S.-based Keysight Technologies ( KEYS )

will buy Spirent Communications ( SPNUF ) in an all-cash

deal, valuing the British telecommunications testing firm at

1.16 billion pounds ($1.46 billion), both companies said in a

joint statement on Thursday.

Spirent withdrew its support for Viavi Solutions' ( VIAV )

offer of 1.01 billion pounds in favour of Keysight's ( KEYS ) higher

offer.

($1 = 0.7922 pounds)

(Reporting by Prerna Bedi in Bengaluru; Editing by Janane

Venkatraman

)

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AI lending platform Upstart Q3 revenue rises
AI lending platform Upstart Q3 revenue rises
Nov 4, 2025
Overview * Upstart Q3 revenue rises 71% YoY, driven by 80% growth in loan originations * GAAP net income for Q3 improves to $31.8 mln from a loss last year * Adjusted EBITDA for Q3 increases to $71.2 mln, reflecting operational efficiency Outlook * Upstart expects Q4 2025 revenue of approximately $288 mln * Company anticipates Q4 2025 GAAP net...
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Latham Group misses Q3 sales estimates, narrows 2025 net sales guidance
Nov 4, 2025
Overview * Latham Group ( SWIM ) Q3 net sales grow 7.6% but miss analyst expectations * Adjusted EBITDA for Q3 beats analyst estimates, reflecting strong operational performance * Gross margin expanded by 300 basis points due to acquisitions and operational efficiencies Outlook * Latham narrows 2025 net sales guidance to $540-$550 mln * Adjusted EBITDA guidance for 2025 revised...
Cellular therapy developer Longeveron's Q3 net loss widens
Cellular therapy developer Longeveron's Q3 net loss widens
Nov 4, 2025
Overview * Net loss for Q3 widened to $7.2 mln, driven by increased R&D expenses * Company anticipates pivotal trial results for laromestrocel in 2026, potential BLA submission in 2027 Result Drivers * REVENUE DECLINE - Decrease in revenue driven by reduced demand for Bahamas Registry Trial and contract manufacturing services * R&D EXPENSES - Increase in R&D expenses due...
Exelixis Q3 revenue beats analyst expectations
Exelixis Q3 revenue beats analyst expectations
Nov 4, 2025
Overview * Exelixis ( EXEL ) Q3 revenue of $597.8 mln beats analyst expectations * Adjusted net income for Q3 beats consensus * Company announces $750 mln stock repurchase program Outlook * Exelixis ( EXEL ) raises 2025 total revenue guidance to $2.30 bln-$2.35 bln * Company lowers 2025 R&D expenses forecast to $850 mln-$900 mln * Exelixis ( EXEL...
Copyright 2023-2026 - www.financetom.com All Rights Reserved